Block Listing 6 Monthly Return

RNS Number : 8285G

Shield Therapeutics PLC

31 March 2022

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Block Listing 6 Monthly Return

Date: 31 March 2022

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		S hield Therapeutics Retention Share Plan
Period of return:	From:	30 September 2021	To:	31 March 2022
Balance of unallotted securities under scheme(s) from previous return:		39,794
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		39,794

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan
Period of return:	From:	30 September 2021	To:	31 March 2022
Balance of unallotted securities under scheme(s) from previous return:		388,079
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		-47,059
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		341,020

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan
Period of return:	From:	30 September 2021	To:	31 March 2022
Balance of unallotted securities under scheme(s) from previous return:		24,273
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		24,273

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan
Period of return:	From:	30 September 2021	To:	31 March 2022
Balance of unallotted securities under scheme(s) from previous return:		3,178,276
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		3,178,276

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	[phone]

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	[phone]
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/Alice Lane/George Dollemore	[phone]
Financial PR & IR Advisor
Walbrook PR (UK Advisor)
Paul McManus/Lianne Applegarth/Alice Woodings Investor Contact (US Advisor)	[phone] or  [e-mail]
LifeSci Advisors, LLC John Mullaly	[phone] or [e-mail]

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer ® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

BLRJBMITMTJJBLT